A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

Official record

Identifier

NCT07570173

Recruiting locations

countries

DenmarkGreeceIsraelItalyJapanNetherlandsSpainSweden

Interventions studied

MK-1045BlinatumomabAcetaminophenDiphenhydramineDexamethasoneTocilizumabSiltuximabAvtozmaTyenne

Lead sponsor

Merck Sharp & Dohme LLC

Target enrolment

340 participants

Study type

INTERVENTIONAL

Phase

Phase 2/3

Status

Recruiting

First posted

May 6, 2026

Last updated on the registry

Sep 25, 2026

Age

12 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Has a confirmed diagnosis of relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) with 5% or more lymphoblasts in the bone marrow
* Has CD19+ disease, confirmed by local flow cytometry and/or immunohistochemistry testing at the time of enrollment
* Has Philadelphia-negative disease, confirmed by testing, at the time of enrollment
* Participants who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or baseline
* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)

Exclusion Criteria:

* Has Burkitt's leukemia
* History or presence of clinically relevant central nervous system (CNS) diseases such as epilepsy, hemorrhagic/ischemic stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, and psychosis
* Has active acute graft versus host disease (GvHD) or chronic GvHD. NOTE: Participants who have received CNI for GvHD within 4 weeks before the first dose of study intervention are also excluded
* History of serious cardiovascular and cerebrovascular diseases.
* HIV-infection with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
* Received prior treatment with blinatumomab within 12 weeks for Part 1 and 24 weeks for Part 2 before the first dose of study intervention (individuals known to be refractory or intolerant to blinatumomab are to be excluded). Refractory to blinatumomab is defined as failure to achieve a response after at least 2 cycles of previous blinatumomab treatment
* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
* Known additional malignancy that is progressing or has required active treatment within the past 2 years
* Isolated extramedullary disease (EMD)
* Active autoimmune disease unrelated to ALL that has required systemic treatment in the past 2 years or history of autoimmune disease with potential CNS involvement
* Active infection requiring systemic therapy
* Has not adequately recovered from major surgery or have ongoing surgical complications

Indexed under

Lymphoma